ArticleIrish journal of medical science2026
Immunomodulatory effects of amisulpride on mammalian macrophages.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between psychiatric disorders and the immune system has become increasingly recognized, with inflammatory pathways implicated in disease pathogenesis, therapeutic response, and progression. Amisulpride, an atypical antipsychotic preferentially acting as an antagonist on postsynaptic D2/D3 receptors, has been widely studied for its psychiatric effects, whereas its immunomodulatory properties remain largely unexplored.
aimWe investigated the potential immunomodulatory effects of amisulpride on J774.2 macrophage cells.
methodsJ774.2 macrophage cells were treated with amisulpride at concentrations of 1, 5, and 10 μg/mL for 24 hours. Cytotoxicity was assessed, and proinflammatory cytokine production (TNF-α, GMCSF, IL-6, IL-12p40) was measured by ELISA under both basal and LPS-induced inflammatory conditions.
resultsAmisulpride demonstrated no cytotoxicity at any concentration. Under non-inflammatory conditions, cytokine levels remained unchanged. In contrast, upon LPS-induced inflammation, amisulpride elicited a dose-dependent anti-inflammatory response, significantly reducing cytokine secretion.
conclusionAmisulpride exhibits immunomodulatory activity under inflammatory conditions. These findings suggest a potential anti-inflammatory mechanism that warrants further investigation.
Indexed as
Identifiers
41288912What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.